Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of PEG-Intron in Heavily Treatment-experienced, HIV-infected Patients

NCT00035360 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00035360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00035360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of PEG-Intron in Heavily Treatment-experienced, HIV-infected Patients
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2002
Completion date
October 31, 2003
Enrollment
49 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aids, hiv infections